The antibody “reactome” is the set of possible binding interactions between antibodies and antigens. Defining each antibody reactome involves interrogation with comprehensive antigen libraries.
Powered by advanced DNA synthesis and sequencing, our novel Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology enables decoding of the antibody reactome using:
”“The new MIPSA technology offered by Infinity Bio is a game changer that allows us to characterize rapidly the allergome of companion animal species. This collaboration saves us years of work! The Infinity Bio team is professional, responsive, and highly competent"
Thierry OlivryHead of R&D | Nextmune, Stockholm, Sweden
”"Infinity Bio offers cutting edge science and technology. Its competitive pricing and high throughput capability makes it ideal for processing large numbers of samples in a timely and efficient manner. Greatly appreciated is the expertise of their staff and the guidance that they provide to make the science successful. They are great partners in our research!"
Jeffrey KrischerPh.D, M.D. (h.c.) | USF
”"Infinity bio attracted our interest since we for a long time had plans to search for autoantibodies and viral antibodies in our large collections of samples and this company can now help us with state-of-the art technology, which is great. We are excited to test the novel technology provided by Infinity Bio to test whether this can advance our research into new avenues. I am impressed by the speed and excellent service provided by Infinity Bio, the set-up of the experiment, logistics and analyses have worked very well so far."
Peter BergmanMD. PhD. Professor | Karolinska Institut
”"We were looking at ways to interrogate the full antibody repertoire of children following measles infection versus controls who have not had measles. We were aware of the work with PhIP-Seq originally in measles and MIPSA is an advancement on this technology. We also liked that we could add custom libraries to fit our purposes (endemic pathogens in select regions in Africa). The ability to use small volumes of specimens and the assistance with all of the analysis were also attractive to us. This will help us with speed in publishing and disseminating the results. Infinity Bio has been helpful at each step for us from the science to the business."
Lead Scientist NIAID(Disclaimer: this is a personal statement and not an official statement of NIAID)
Antibody reactome analyses help researchers and clinicians understand the immune status of individuals or groups and identify immune-related patterns that will one day be used to personalize treatments or interventions across a variety of indications.
Gain insight into an individual or a population’s immune responses against specific pathogen proteins or vaccine components to support the discovery of complex disease mechanisms and the development of improved diagnostics.
Uncover molecular targets and patterns of reactivity associated with autoimmune diseases, such as lupus, multiple sclerosis, scleroderma, etc.
Identify key epitopes to reveal crucial mechanistic correlates of vaccine efficacy.
Characterize allergic antibodies, including those targeting food and environmental allergens (e.g., pollen, dust mites), to better understand and characterize the reactivities – at epitope resolution – involved in immune reactions.
Assess the immune response against cancer cells by identifying tumor-specific antibodies and evaluating efficacy and adverse events after immunotherapeutic intervention.
Discover novel therapeutic targets or biomarkers associated with various diseases.
Inform gene, microbiome, and immunomodulatory therapies with a better understanding of each individual’s unique antibody repertoire.
Bespoke libraries covering any set of protein sequences across any kingdom of life
Learn MoreInfinity Bio provides standard reporting and offers fee-for-service statistical analyses. Our biostatisticians are available to ensure your antibody reactome studies yield maximal inSIGHT.
